This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

UPLYSO(TM) (alfataliglicerase) Approved In Brazil By ANVISA For The Treatment Of Gaucher Disease

On November 30, 2009, Protalix entered into an agreement with Pfizer to develop and commercialize taliglucerase alfa/alfataliglicerase. Under the terms of the agreement, Protalix retained the exclusive commercialization rights in Israel, while Pfizer received exclusive licensing rights for commercialization in all other markets.

Indication for UPLYSO in Brazil

UPLYSO (alfataliglicerase) is indicated for long-term enzyme replacement therapy for adults with a confirmed diagnosis of Type I Gaucher disease. The manifestations of Gaucher disease may include one or more of the following: splenomegaly, hepatomegaly, anemia, thrombocytopenia, bone disease.

Important Safety Information for UPLYSO in Brazil

As with any intravenous protein medicine, like enzyme replacement therapy (ERT), UPLYSO may cause infusion-related reactions (i.e., occurring during or shortly after infusion) and hypersensitivity reactions. If a severe allergic reaction occurs, immediate discontinuation of the alfataliglicerase infusion is recommended. Patients who experience reactions of hypersensitivity or related to the infusion, can however be managed successfully. The therapy can be continued by slowing the infusion rate, treating with medicinal products such as antihistamines, antipyretics and/or corticosteroids, and/or stopping and resuming treatment with decreased infusion rate. Pre-treatment with antihistamines and/or corticosteroids may prevent subsequent reactions.

The most commonly observed infusion reactions were headache, hypersensitivity (allergic reaction), dizziness, flushing (redness), throat irritation, nausea (qualm), pruritus (itch), erythema (redness), rash, bone pain, back pain, arthralgia (joint pain), among others.

Also, there is a possibility of developing antibodies to UPLYSO. However, it is currently unclear whether this has an impact on the clinical response or adverse reactions. Patients with an immune response to other ERTs who are switching to UPLYSO should continue to be monitored for antibodies. Patients who have developed infusion or immune reactions with UPLYSO or with another ERT should be monitored for antidrug antibodies when being treated with UPLYSO.

If you are pregnant, or plan to become pregnant, you should talk to your doctor about potential benefits and risks.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $92.96 -2.00%
FB $117.99 1.10%
GOOG $698.04 1.00%
TSLA $237.81 -4.00%
YHOO $36.62 0.08%


Chart of I:DJI
DOW 17,810.62 +36.98 0.21%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs